Free tools Windows power users keep installed
One-click scans. No signup required.
Total synthesis lets chemists build an antibiotic molecule from simpler starting materials, then alter its structure to investigate how it works and whether changes can improve its activity. It is a research tool, not a shortcut to an approved medicine: promising activity in laboratory or animal studies still leaves human safety, efficacy, manufacturing and regulatory review to establish.
How are scientists creating new antibiotics?
In total synthesis, chemists construct a molecule completely from simpler starting materials rather than relying on the organism or biological pathway that naturally makes it. The approach can make complex antibiotic structures available for experiments and, when a route can be varied, for producing related compounds called analogues.
As an Amazon Associate I earn from qualifying purchases.
Those analogues help researchers examine structure–activity relationships: how changes in a molecule’s structure affect its interaction with bacterial targets and its ability to inhibit bacteria. A practical, diversifiable synthetic route can therefore support systematic study of antibiotic scaffolds. A 2014 review by Wright, Seiple and Myers presents this as a research advantage, not a guarantee that any resulting compound will become a treatment.
Quick wins for a faster PC:
Repair Windows errors before they cause bigger problemsFix Now →Fix the driver behind crashes, sound loss and screen glitchesFind Drivers →Can synthetic chemistry help overcome antibiotic resistance?
It can help researchers explore that question. Chemists may use knowledge of a bacterial target and existing antibiotics to design compounds with altered structures, then test whether they retain activity against resistant bacteria. That is a way to investigate possible responses to resistance, not evidence that resistance has been solved or that a candidate will work in patients.
#1 Best Overall
Cresomycin: a synthetic candidate designed around the ribosome
NIH’s March 2024 account describes cresomycin as a fully synthetic, lincosamide-inspired antibiotic candidate designed using structural knowledge of how lincosamides bind to bacterial ribosomes. The report describes activity against gram-positive and gram-negative bacteria, including resistant strains, along with experiments in mice. NIH stated at publication that cresomycin had not been tested in people; that dated statement does not establish its status in October 2026. Read the NIH report.
In one reported mouse experiment, all 10 mice treated with cresomycin survived for seven days after a lethal infection with resistant Staphylococcus aureus; 9 of 10 untreated mice died within two days. This is an animal result from one experiment, not a human outcome.
Rank #2
Teixobactin, Malacidin A and Kynomycin
A May 2024 bulletin from the University of Hong Kong says its group achieved total synthesis of teixobactin and Malacidin A and prepared more than 100 teixobactin analogues. It also reported that Kynomycin had been approved for clinical trials in mainland China at that time. The bulletin’s dated report is not a current trial-registry check, so it should not be read as establishing any candidate’s present clinical status. Read the HKU bulletin.
What synthesis can—and cannot—tell researchers
Building a molecule and making analogues can give researchers material to study its structure and biological effects. But a compound’s activity in cells or animals is an early signal, not proof that it is safe or effective in people. Clinical testing, feasible manufacturing and regulatory approval are separate challenges. Andrew Myers, identified by NIH as a Harvard University researcher, put the uncertainty plainly in the March 2024 report: “We don’t yet know whether cresomycin and drugs like it are safe and effective in humans.”
Rank #3
Chemical synthesis and biosynthesis are complementary routes
Total synthesis is not the only way to obtain or study an antibiotic. Biosynthesis uses biological machinery, such as a microorganism’s pathway, to make molecules. Researchers may also investigate how to engineer those pathways when natural production is insufficient. Which route is useful depends on the molecule and the research or production goal; the available reports do not establish a universal winner.
| Research consideration | Chemical synthesis | Biosynthesis and pathway engineering |
|---|---|---|
| Access and diversification | A practical route may provide access to a scaffold and allow analogues to be made for study. | Pathway understanding may point to ways to alter biological production; the odilorhabdin report describes this as a potential direction. |
| Material for study | Synthetic routes can supply material for structural and biological experiments, though the sources provide no comparable yields for the named examples. | Natural microbial yields can be low; the odilorhabdin team studied biosynthesis with improved production as a possible aim. |
| Technical challenges | Complex stereochemistry and macrocycle formation can complicate construction. | Production depends on biological pathways that may need to be understood or engineered. |
| Cost, scale and practicality | No direct, comparable cost or yield analysis for these examples is reported in the cited sources. | No direct, comparable cost or yield analysis for these examples is reported in the cited sources. |
Odilorhabdin and learning from a natural pathway
In June 2024, the Max Planck Society reported that researchers elucidated odilorhabdin biosynthesis and identified a basis for future pathway engineering, noting low microbial yields. The work points to a possible biotechnological production route; it does not show that biosynthesis replaced chemical synthesis or that odilorhabdin reached clinical use. Team leader Helge Bode explained: “The advantage of our approach is that we can use this technique to elucidate the biosynthesis without having the whole product in hand.” Read the Max Planck Society report.
Quick Recap
What to take away
- Total synthesis is a way to construct and modify antibiotic molecules for research, including studies of how structure relates to activity.
- Cresomycin, teixobactin and Malacidin A illustrate synthetic chemistry applied to antibiotic candidates or scaffolds; their reported findings and development claims are time-bound to the cited reports.
- Biosynthetic pathway research offers a complementary way to understand and potentially improve microbial production.
- Neither a successful synthesis nor promising preclinical results establish a safe, effective, manufacturable, approved human medicine.
Product prices and availability are accurate as of the date/time indicated and are subject to change. Any price and availability information displayed on Amazon at the time of purchase will apply.
The Tool Desk
Outbyte PC Repair FREEClear out junk files and repair common Windows errorsFree Scan →Outbyte Driver Updater FREEFix the driver behind crashes, sound loss and screen glitchesFind Drivers →
